The present invention is directed to VEGFR-3 ligand binding molecules and uses thereof to modulate angiogenesis and/or lymphangiogenesis. A glycosylation sequon of wildtype VEGFR-3 has been modified to eliminate glycosylation in the ligand binding molecules.La présente invention concerne des molécules de liaisons à des ligands ainsi que leurs utilisations pour moduler l'angiogenèse et/ou la lymphangiogenèse.